VDAC1 and prostate cancer: Other examples include arbutin (hydroquinone-O-beta-d-glucopyranoside), a tyrosinase inhibitor in A375 human malignant melanoma cells (176), and somatostatin, used in the treatment of advanced prostate cancer, which upregulated the expression of VDAC1 and VDAC2 in the LNCaP prostate cancer cell line (177).